Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2023-07-11
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is to discover if the oral Etoposide plus Anlotinib can shrink
or slow the growth of pretreated advanced TNBC.
It is a single-arm, multicenter phase II clinical study of oral etoposide combined with
antinib in the treatment of recurrent or metastatic triple-negative breast cancer